SLC5A2 and type 2 diabetes mellitus: However, the consistency of effect size on a range of cardiovascular and kidney outcomes supports the likely beneficial effects of SGLT2 inhibitors in patients with type 2 diabetes mellitus at high cardiovascular risk.